We further unveiled that the TP53 variant in pro-B-ALL SEM and the BCL-6–BIM axis can probably explain the entospletinib sensitivity and therefor provides a rationale for Ento application also in a subset of pro-B-ALL. This evidence concerns the gene BCL6 and acute lymphoblastic leukemia.